{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:19:40Z","timestamp":1794694780718,"version":"4.9.1"},"reference-count":166,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer progression and therapeutic resistance are driven by complex molecular interactions between genomic instability and immune modulation. Defects in the DNA damage response (DDR) not only promote tumor heterogeneity but also shape the tumor immune landscape through the generation of neoantigens, activation of the cGAS\u2013STING pathway, and modulation of immune checkpoints. This review provides an integrative overview of the molecular mechanisms linking DDR dysfunction to immune crosstalk, emphasizing how these processes influence tumor evolution and response to therapy. We discuss emerging therapeutic strategies that exploit DDR\u2013immune interactions, including PARP and ATR inhibitors, synthetic lethality approaches, and combination regimens with immune checkpoint blockade. Understanding the bidirectional connection between DNA repair pathways and immune signaling unveils new translational opportunities for precision oncology and offers a framework for developing combinatorial therapies capable of overcoming resistance and improving long-term cancer control.<\/jats:p>","DOI":"10.3390\/ijms262311271","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:41:58Z","timestamp":1763728918000},"page":"11271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities"],"prefix":"10.3390","volume":"26","author":[{"given":"Lavinia","family":"Marcut","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Daniela","family":"Brata","sequence":"additional","affiliation":[{"name":"Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Cristina","family":"Barb","sequence":"additional","affiliation":[{"name":"Department II of Microscopic Morphology, Discipline of Histology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3410-3870","authenticated-orcid":false,"given":"Alexia","family":"Manole","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Gabriel","family":"Stef","sequence":"additional","affiliation":[{"name":"Department IX, Discipline of Surgical Semiology I, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-3060","authenticated-orcid":false,"given":"Cristina Stefania","family":"Dumitru","sequence":"additional","affiliation":[{"name":"Department II of Microscopic Morphology, Discipline of Histology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-179X","authenticated-orcid":false,"given":"Flavia","family":"Zara","sequence":"additional","affiliation":[{"name":"Department II of Microscopic Morphology, Discipline of Histology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Patrascu","sequence":"additional","affiliation":[{"name":"Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-Damage Response in Human Biology and Disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic Opportunities within the DNA Damage Response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent Innate Immune Signaling by S-Phase-Specific DNA Damage in Breast Cancer","volume":"109","author":"Parkes","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA Sensing by the cGAS\u2013STING Pathway in Health and Disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-Cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The Cytosolic DNA-Sensing cGAS\u2013STING Pathway in Cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic Progression Following DNA Damage Enables Pattern Recognition within Micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","article-title":"BRCA2 Abrogation Triggers Innate Immune Responses Potentiated by Treatment with PARP Inhibitors","volume":"10","author":"Lombardi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR Inhibition Potentiates the Radiation-Induced Inflammatory Tumor Microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e3001720","DOI":"10.1371\/journal.pbio.3001720","article-title":"Expanding the Epitranscriptome: Dihydrouridine in mRNA","volume":"20","author":"Dixit","year":"2022","journal-title":"PLoS Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA Damage Response: Making It Safe to Play with Knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrm.2017.21","article-title":"The Development and Functions of Multiciliated Epithelia","volume":"18","author":"Spassky","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrc1075","article-title":"Tumour-Cell Invasion and Migration: Diversity and Escape Mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","first-page":"551","article-title":"RIP Endothelial Cells","volume":"16","author":"Dart","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1078-0432.CCR-14-3214","article-title":"Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?","volume":"21","author":"Cox","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103879","DOI":"10.1016\/j.dnarep.2025.103879","article-title":"Base Excision Repair in Human Cancer: Emerging Diagnostic and Therapeutic Target","volume":"152","author":"Zhou","year":"2025","journal-title":"DNA Repair"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41467-019-10745-5","article-title":"Structural Basis of TFIIH Activation for Nucleotide Excision Repair","volume":"10","author":"Kokic","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/nar\/gkac1095","article-title":"A Scanning-to-Incision Switch in TFIIH\u2013XPG Induced by DNA Damage Licenses Nucleotide Excision Repair","volume":"51","author":"Tehseen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103568","DOI":"10.1016\/j.dnarep.2023.103568","article-title":"TFIIH Central Activity in Nucleotide Excision Repair to Prevent Disease","volume":"132","author":"Theil","year":"2023","journal-title":"DNA Repair"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zachayus, A., Loup-Forest, J., Cura, V., and Poterszman, A. (2025). Nucleotide Excision Repair: Insights into Canonical and Emerging Functions of the Transcription\/DNA Repair Factor TFIIH. Genes, 16.","DOI":"10.3390\/genes16020231"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nature23903","article-title":"The Cryo-Electron Microscopy Structure of Human Transcription Factor IIH","volume":"549","author":"Greber","year":"2017","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e44771","DOI":"10.7554\/eLife.44771","article-title":"The Complete Structure of the Human TFIIH Core Complex","volume":"8","author":"Greber","year":"2019","journal-title":"eLife"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrg2663","article-title":"Disorders of Nucleotide Excision Repair: The Genetic and Molecular Basis of Heterogeneity","volume":"10","author":"Cleaver","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"zcae013","DOI":"10.1093\/narcan\/zcae013","article-title":"XPA Tumor Variant Leads to Defects in NER That Sensitize Cells to Cisplatin","volume":"6","author":"Blee","year":"2024","journal-title":"NAR Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO Recommendations on Microsatellite Instability Testing for Immunotherapy in Cancer, and Its Relationship with PD-1\/PD-L1 Expression and Tumour Mutational Burden: A Systematic Review-Based Approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1611719","DOI":"10.3389\/pore.2024.1611719","article-title":"Microsatellite Instability and Mismatch Repair Protein Deficiency: Equal Predictive Markers?","volume":"30","author":"Lotz","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 Foci as a Functional Biomarker of Homologous Recombination Repair and PARP Inhibitor Resistance in Germline BRCA-Mutated Breast Cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101255","DOI":"10.1016\/j.xcrm.2023.101255","article-title":"Widespread BRCA1\/2-Independent Homologous Recombination Defects Are Caused by Alterations in RNA-Binding Proteins","volume":"4","author":"McGrail","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"oyaf141","DOI":"10.1093\/oncolo\/oyaf141","article-title":"The Prognostic and Predictive Value of Homologous Recombination Deficiency in Gastrointestinal Cancer","volume":"30","author":"Jiang","year":"2025","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-Homologous DNA End Joining and Alternative Pathways to Double-Strand Break Repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103553","DOI":"10.1016\/j.dnarep.2023.103553","article-title":"Holding It Together: DNA End Synapsis during Non-Homologous End Joining","volume":"130","author":"Loparo","year":"2023","journal-title":"DNA Repair"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.molcel.2023.01.012","article-title":"Two Distinct Long-Range Synaptic Complexes Promote Different Aspects of End Processing Prior to Repair of DNA Breaks by Non-Homologous End Joining","volume":"83","author":"Buehl","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, L.Y., Guan, Y.D., Chen, X.S., Yang, J.M., and Cheng, Y. (2021). DNA Repair Pathways in Cancer Therapy and Resistance. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.629266"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102496","DOI":"10.1016\/j.coph.2024.102496","article-title":"Regulation of Pathway Choice in DNA Repair after Double-Strand Breaks","volume":"80","author":"Kumari","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Xu, J., Bradley, N., and He, Y. (2023). Structure and Function of the Apical PIKKs in Double-Strand Break Repair. Curr. Opin. Struct. Biol., 82.","DOI":"10.1016\/j.sbi.2023.102651"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1474337","DOI":"10.3389\/fphar.2024.1474337","article-title":"Advancing Cancer Therapy: New Frontiers in Targeting DNA Damage Response","volume":"15","author":"Qian","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-020-0376-x","article-title":"ATM, ATR and DNA-PKcs Kinases\u2014The Lessons from the Mouse Models: Inhibition \u2260 Deletion","volume":"10","author":"Menolfi","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tcb.2023.02.003","article-title":"Molecular Mechanisms of Nucleolar DNA Damage Checkpoint Response","volume":"33","author":"Li","year":"2023","journal-title":"Trends Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Soni, A., Duan, X., Stuschke, M., and Iliakis, G. (2022). ATR Contributes More Than ATM in Intra-S-Phase Checkpoint Activation after IR, and DNA-PKcs Facilitates Recovery: Evidence for Modular Integration of ATM\/ATR\/DNA-PKcs Functions. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147506"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ceb.2007.02.009","article-title":"DNA Damage Checkpoints: From Initiation to Recovery or Adaptation","volume":"19","author":"Bartek","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA Damage Response: Putting Checkpoints in Perspective","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"150517","DOI":"10.1016\/j.bbrc.2024.150517","article-title":"Simultaneous Inhibition of ATM, ATR, and DNA-PK Causes Synergistic Lethality","volume":"738","author":"Kato","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The Repertoire of Mutational Signatures in Human Cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_47","first-page":"708","article-title":"Tumour Biomarkers: A Mark Is a Marker","volume":"17","author":"Harjes","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"797880","DOI":"10.3389\/fimmu.2021.797880","article-title":"Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete Loss of ATM Function Augments Replication Catastrophe Induced by ATR Inhibition and Gemcitabine in Pancreatic Cancer Models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical Approaches to Overcome PARP Inhibitor Resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR Screens Reveal Genetic Determinants of PARP Inhibitor Sensitivity and Resistance in Prostate Cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2020.03.005","article-title":"KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer","volume":"37","author":"Alam","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/molbev\/msu046","article-title":"Emergence and Evolutionary Analysis of the Human DDR Network: Implications in Comparative Genomics and Downstream Analyses","volume":"31","author":"Arcas","year":"2014","journal-title":"Mol. Biol. Evol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri.2017.102","article-title":"Nuclear Waste Ignites cGAS","volume":"17","author":"Bordon","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","article-title":"Regulation of cGAS\u2013STING Signalling and Its Diversity of Cellular Outcomes","volume":"25","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1016\/j.molcel.2025.08.030","article-title":"Activation and Regulation of cGAS\u2013STING Signaling in Cancer Cells","volume":"85","author":"Shim","year":"2025","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS\u2013STING Pathway Mediates Activation of Dendritic Cell Sensing of Immunogenic Tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-Intrinsic Resistance to Immune Checkpoint Blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-Tumor Immunity","volume":"25","author":"Sivick","year":"2018","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Nerdinger, Y.G., Binder, A.K., Bremm, F., Feuchter, N., Schaft, N., and D\u00f6rrie, J. (2025). STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26189008"},{"key":"ref_68","first-page":"101074","article-title":"Precision Targeting of STING: Challenges, Innovations, and Clinical Outlook for Cancer Therapy","volume":"6","author":"Shi","year":"2025","journal-title":"Innovation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS\u2013STING Pathway in Cancer Biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","article-title":"The Role of DNA Damage Repair (DDR) System in Response to Immune Checkpoint Inhibitor (ICI) Therapy","volume":"41","author":"Shi","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA Damage Response Pathways in Cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.immuni.2014.09.019","article-title":"LOX-1 Unlocks Human Plasma Cell Potential","volume":"41","author":"Brink","year":"2014","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal Instability Drives Metastasis through a Cytosolic DNA Response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41590-024-01872-3","article-title":"The Balance of STING Signaling Orchestrates Immunity in Cancer","volume":"25","author":"Lanng","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_76","unstructured":"U.S. Food & Drug Administration (2025, November 19). FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/Site-Agnostic Indication. U.S. FDA 2017, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The Role of Neoantigens and Tumor Mutational Burden in Cancer Immunotherapy: Advances, Mechanisms, and Perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1617654","DOI":"10.3389\/fimmu.2025.1617654","article-title":"Advances and Challenges in Neoantigen Prediction for Cancer Immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nm.4317","article-title":"Autoimmune T Cell Recognition of Alternative-Reading-Frame-Encoded Peptides","volume":"23","author":"Wei","year":"2017","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","article-title":"Cancer Immunoediting in the Era of Immuno-Oncology","volume":"28","author":"Gubin","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.cell.2021.04.031","article-title":"Coming to America: Genomic Surveillance and How B.1.1.7 Arrived in the US","volume":"184","author":"Qiu","year":"2021","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I Interferon Activates MHC Class I-Dressed CD11b+ Conventional Dendritic Cells to Promote Protective Anti-Tumor CD8+ T Cell Immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e1546068","DOI":"10.1080\/2162402X.2018.1546068","article-title":"Batf3+ DCs and Type I IFN Are Critical for the Efficacy of Neoadjuvant Cancer Immunotherapy","volume":"8","author":"Liu","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zannikou, M., Fish, E.N., and Platanias, L.C. (2024). Signaling by Type I Interferons in Immune Cells: Disease Consequences. Cancers, 16.","DOI":"10.3390\/cancers16081600"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","article-title":"How Cancer Cells Make and Respond to Interferon-I","volume":"9","author":"Cheon","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e2112258118","DOI":"10.1073\/pnas.2112258118","article-title":"PD-L1 Sustains Chronic, Cancer Cell-Intrinsic Responses to Type I Interferon, Enhancing Resistance to DNA Damage","volume":"118","author":"Cheon","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Jiang, J., Yan, Y., Yang, C., and Cai, H. (2025). Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040950"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"111647","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic Type I Interferon Signaling Promotes Lipid-Peroxidation-Driven Terminal CD8+ T Cell Exhaustion and Curtails Anti-PD-1 Efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12964-025-02069-3","article-title":"Intrinsic STING of CD8+ T Cells Regulates Self-Metabolic Reprogramming and Memory to Exert Anti-Tumor Effects","volume":"23","author":"Xu","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1476904","DOI":"10.3389\/fimmu.2024.1476904","article-title":"CD8+ T Cell Exhaustion and Its Regulatory Mechanisms in the Tumor Microenvironment: Key to the Success of Immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41416-018-0017-x","article-title":"From Checkpoint to Checkpoint: DNA Damage ATR\/Chk1 Checkpoint Signalling Elicits PD-L1 Immune Checkpoint Activation","volume":"118","author":"Mouw","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"998388","DOI":"10.3389\/fonc.2022.998388","article-title":"Anti-Cancer Immune Responses to DNA Damage Response Inhibitors: Molecular Mechanisms and Progress toward Clinical Translation","volume":"12","author":"Carlsen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA Damage Response Pathway: Biomarker and Therapeutic Strategy for Cancer Immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ali, U., Vungarala, S., and Tiriveedhi, V. (2024). Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy. Genes, 15.","DOI":"10.3390\/genes15020162"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e217728","DOI":"10.1001\/jamanetworkopen.2021.7728","article-title":"Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors","volume":"4","author":"Zhou","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP Inhibition Elicits STING-Dependent Antitumor Immunity in BRCA1-Deficient Ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-022-06780-4","article-title":"Emerging Strategies: PARP Inhibitors in Combination with Immune Checkpoint Blockade in BRCA1- and BRCA2-Mutation-Associated and Triple-Negative Breast Cancer","volume":"197","author":"Gupta","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","article-title":"STING Agonism Enhances Anti-Tumor Immune Responses and Therapeutic Efficacy of PARP Inhibition in BRCA-Associated Breast Cancer","volume":"8","author":"Pantelidou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and Durvalumab in Patients with Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a Novel ATR Inhibitor, Demonstrates In Vivo Activity in ATRX-Mutated Models of Uterine Leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Revia, S., Neumann, F., Jabs, J., Orio, F., Sirrenberg, C., Zimmermann, A., Amendt, C., and Albers, J. (2024). Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105120"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"729136","DOI":"10.3389\/fcell.2021.729136","article-title":"DNA Damage-Induced Inflammatory Microenvironment and Adult Stem Cell Response","volume":"9","author":"Cinat","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11596-024-2859-1","article-title":"DNA Damage-Driven Inflammatory Cytokines: Reprogramming of Tumor Immune Microenvironment and Application of Oncotherapy","volume":"44","author":"Wang","year":"2024","journal-title":"Curr. Med. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"867098","DOI":"10.3389\/fimmu.2022.867098","article-title":"Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity","volume":"13","author":"Tuomela","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.immuni.2025.07.012","article-title":"Mitochondria Reactive Oxygen Species Signaling-Dependent Immune Responses in Macrophages and T Cells","volume":"58","author":"Weinberg","year":"2025","journal-title":"Immunity"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood-2015-09-668970","article-title":"DNA Damage Response Impacts Macrophage Functions","volume":"126","author":"Colonna","year":"2015","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"110810","DOI":"10.1016\/j.isci.2024.110810","article-title":"Type I Interferon Signaling Regulates Myeloid and T Cell Crosstalk in the Glioblastoma Tumor Microenvironment","volume":"27","author":"Lim","year":"2024","journal-title":"iScience"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/0008-5472.CAN-25-0831","article-title":"Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer","volume":"85","author":"Gohari","year":"2025","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA Damage and Cancer Immunotherapy: A STING in the Tale","volume":"80","author":"Groelly","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2013STING Pathway in Cancer Immunity: Mechanisms, Challenges, and Therapeutic Implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yu, X., Cai, L., Yao, J., Li, C., and Wang, X. (2024). Agonists and Inhibitors of the cGAS\u2013STING Pathway. Molecules, 29.","DOI":"10.3390\/molecules29133121"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP Inhibitors: A Review of the Pharmacology, Pharmacokinetics, and Pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Franzese, O., and Graziani, G. (2022). Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. Cancers, 14.","DOI":"10.3390\/cancers14225633"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","article-title":"Targeting MHC-I Inhibitory Pathways for Cancer Immunotherapy","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"110814","DOI":"10.1016\/j.celrep.2022.110814","article-title":"WEE1 Inhibition Enhances the Antitumor Immune Response to PD-L1 Blockade by the Concomitant Activation of STING and STAT1 Pathways in SCLC","volume":"39","author":"Taniguchi","year":"2022","journal-title":"Cell Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"762989","DOI":"10.3389\/fimmu.2021.762989","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"viii147","DOI":"10.1093\/annonc\/mdy279.435","article-title":"MEDIOLA: A Phase I\/II Trial of Olaparib (PARP Inhibitor) in Combination with Durvalumab (Anti-PD-L1 Antibody) in Patients with Advanced Solid Tumours\u2014New Ovarian Cancer Cohorts","volume":"29","author":"Penson","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2025-CT004","article-title":"Abstract CT004: KEYLYNK-007: Tumor-Agnostic Trial of Olaparib plus Pembrolizumab in Homologous Recombination Repair Mutation- and Homologous Recombination Deficiency-Positive Advanced Cancers","volume":"85","author":"Yap","year":"2025","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR Inhibitor Ceralasertib Potentiates Cancer Checkpoint Immunotherapy by Regulating the Tumor Microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e175369","DOI":"10.1172\/JCI175369","article-title":"Durable Responses to ATR Inhibition with Ceralasertib in Tumors with Genomic Defects and High Inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","article-title":"Phase I Trial of ATR Inhibitor Elimusertib with FOLFIRI in Advanced or Metastatic Gastrointestinal Malignancies (ETCTN 10406)","volume":"95","author":"Krishnamurthy","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kim, M., Min, A., Kim, S., Kim, S., Kim, Y.J., Ham, S., Lee, M., Lee, E.Y., Kim, J., and Lee, D.W. (Cancer Res. Treat., 2025). Elimusertib, a Novel ATR Inhibitor, Induces Anti-Tumor Effects through Replication Catastrophe in Breast Cancers, Cancer Res. Treat., Online ahead of print.","DOI":"10.4143\/crt.2024.1105"},{"key":"ref_126","unstructured":"(2025). Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumour Malignancies (MEDIPAC), National University Hospital. ClinicalTrials.Gov, NCT03772561."},{"key":"ref_127","unstructured":"(2025). Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors, M.D. Anderson Cancer Center. ClinicalTrials.Gov, NCT04266912."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1158\/1538-7445.AM2025-590","article-title":"Prostate specific membrane antigen targeted PRMT5 inhibition re-sensitizes cancer cells to radiation therapies [abstract]","volume":"85","author":"Sengupta","year":"2025","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1485303","DOI":"10.3389\/fimmu.2024.1485303","article-title":"Efficacy and Safety of PD-1\/PD-L1 and CTLA-4 Immune Checkpoint Inhibitors in the Treatment of Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"McNeil, V., and Lee, S.W. (2025). Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies. Cancers, 17.","DOI":"10.3390\/cancers17091408"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/s12967-024-05583-z","article-title":"Application of PARP Inhibitors Combined with Immune Checkpoint Inhibitors in Ovarian Cancer","volume":"22","author":"Xiao","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP Inhibitors: Enhancing Efficacy through Rational Combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.euo.2025.04.018","article-title":"Patient-Reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib versus Abiraterone or Enzalutamide for Participants with Biomarker-Unselected, Previously Treated Metastatic Castration-Resistant Prostate Cancer","volume":"8","author":"Mehra","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab Plus Olaparib for Patients with Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/1538-7445.AM2025-6964","article-title":"Abstract 6964: Dual Inhibition of PKMYT1 and WEE1 Kinases as a Targeted Therapy for ATIP3-Deficient Breast Cancers","volume":"85","author":"Haykal","year":"2025","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12967-025-06843-2","article-title":"The cGAS\u2013STING Pathway: A Dual Regulator of Immune Response in Cancer and Therapeutic Implications","volume":"23","author":"Huang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to Promote Antitumor Immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS\u2013STING Pathway: Precision Regulation in the Tumor Immune Microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"115596","DOI":"10.1016\/j.bcp.2023.115596","article-title":"Strategies Involving STING Pathway Activation for Cancer Immunotherapy: Mechanism and Agonists","volume":"213","author":"Pan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Ji, N., Wang, M., and Tan, C. (2023). Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020638"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary Results of the First-in-Human (FIH) Study of MK-1454, an Agonist of Stimulator of Interferon Genes (STING), as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors or Lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"eado0082","DOI":"10.1126\/sciadv.ado0082","article-title":"STING Activation Disrupts Tumor Vasculature to Overcome the EPR Limitation and Increase Drug Deposition","volume":"10","author":"Jiang","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e02270","DOI":"10.1002\/advs.202502270","article-title":"Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity","volume":"12","author":"Long","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1158\/0008-5472.CAN-17-3932","article-title":"Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine","volume":"78","author":"Koh","year":"2018","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41698-023-00442-4","article-title":"Relationship among DDR Gene Mutations, TMB and PD-L1 in Solid Tumour Genomes Identified Using Clinically Actionable Biomarker Assays","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Tao, W., Sun, Q., Xu, B., and Wang, R. (2025). Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review. Life, 15.","DOI":"10.3390\/life15020283"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"109304","DOI":"10.1016\/j.intimp.2022.109304","article-title":"Targeting STING for Cancer Immunotherapy: From Mechanisms to Translation","volume":"113","author":"Huang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41698-023-00428-2","article-title":"Chemokine Expression Predicts T Cell-Inflammation and Improved Survival with Checkpoint Inhibition across Solid Cancers","volume":"7","author":"Romero","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.molcel.2022.12.031","article-title":"Combining Targeted DNA Repair Inhibition and Immune-Oncology Approaches for Enhanced Tumor Control","volume":"83","author":"Concannon","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e011308","DOI":"10.1136\/jitc-2024-011308","article-title":"Single-Cell Spatial Transcriptomics Unravels Cell States and Ecosystems Associated with Clinical Response to Immunotherapy","volume":"13","author":"Abdulrahman","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"13922","DOI":"10.3389\/abp.2025.13922","article-title":"Advancements in Single-Cell RNA Sequencing and Spatial Transcriptomics: Transforming Biomedical Research","volume":"72","author":"Birhanu","year":"2025","journal-title":"Acta Biochim. Pol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e010548","DOI":"10.1136\/jitc-2024-010548","article-title":"The Cold Immunological Landscape of ATM-Deficient Cancers","volume":"13","author":"Sinha","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41576-021-00370-8","article-title":"Integrating Single-Cell and Spatial Transcriptomics to Elucidate Intercellular Tissue Dynamics","volume":"22","author":"Longo","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2210845","DOI":"10.1080\/07853890.2023.2210845","article-title":"Anti-Triple-Negative Breast Cancer Metastasis Efficacy and Molecular Mechanism of the STING Agonist for Innate Immune Pathway","volume":"55","author":"Lu","year":"2023","journal-title":"Ann. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1482738","DOI":"10.3389\/fimmu.2024.1482738","article-title":"Targeting STING Signaling for the Optimal Cancer Immunotherapy","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Han","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of Durvalumab plus Olaparib in Metastatic Castration-Resistant Prostate Cancer in Men with and without DNA Damage Repair Mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e165615","DOI":"10.1172\/jci.insight.165615","article-title":"The Schedule of ATR Inhibitor AZD6738 Can Potentiate or Abolish Antitumor Immune Responses to Radiotherapy","volume":"8","author":"Vendetti","year":"2023","journal-title":"JCI Insight"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e70397","DOI":"10.1002\/ctm2.70397","article-title":"Unlocking the Therapeutic Potential of ATR Inhibitors: Advances, Challenges, and Opportunities in Cancer Therapy","volume":"15","author":"Reddy","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e010183","DOI":"10.1136\/jitc-2024-010183","article-title":"Spatial and Single-Cell Transcriptomics Reveal Cellular Heterogeneity and a Novel Cancer-Promoting Treg Cell Subset in Human Clear-Cell Renal Cell Carcinoma","volume":"13","author":"Song","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e202302424","DOI":"10.26508\/lsa.202302424","article-title":"Micronucleus Is Not a Potent Inducer of the cGAS\/STING Pathway","volume":"7","author":"Sato","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-024-02040-9","article-title":"Advances in Spatial Transcriptomics and Its Applications in Cancer Research","volume":"23","author":"Jin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41588-024-01958-6","article-title":"Brca1 Haploinsufficiency Promotes Early Tumor Onset and Epigenetic Alterations in a Mouse Model of Hereditary Breast Cancer","volume":"56","author":"Li","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1002\/ctm2.650","article-title":"Single-Cell Transcriptome Atlas of Human Mesenchymal Stem Cells Exploring Cellular Heterogeneity","volume":"11","author":"Wang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41388-025-03388-y","article-title":"Spatial Multi-Omics Profiling of Breast Cancer Oligo-Recurrent Lung Metastasis","volume":"44","author":"Gao","year":"2025","journal-title":"Oncogene"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","article-title":"Conserved Spatial Subtypes and Cellular Neighborhoods of Cancer-Associated Fibroblasts Revealed by Single-Cell Spatial Multi-Omics","volume":"43","author":"Liu","year":"2025","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:43:48Z","timestamp":1763729028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":166,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311271"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311271","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}